Nach den Quartalszahlen: Biontech: Geht die Party jetzt weiter? Die neuen Kursziele der Analysten | Diskussion im Forum

[faultcode]

Nov. 6, 2023 at 6:59 a.m. ET
BioNTech’s stock rallies after it posts surprise Q3 profit and revenue that tops estimates
https://www.marketwatch.com/story/biontechs-stock-rallies-af…
...
BioNTech SE’s stock BNTX, +3.56% rallied premarket after the company posted a surprise profit for the third quarter and revenue that beat estimates, even as it was hit by lower COVID-19 vaccine revenue. The German company said it had net profit of 160.6 million euros ($172.7 million), or 67 cents a share, down from EUR1.785 billion, or EUR6.98 a share, in the year-earlier period.

Revenue fell to EUR895.3 million from EUR3.461 billion a year ago. The FactSet consensus was for a loss of 59 cents and revenue of EUR851.0 million. The company said inventory writedowns by its partner Pfizer Inc. shaved EUR507.9 million off revenue for the period, which was also reduced by lower COVID-19 vaccine revenue.

The company is now expecting full-year COVID revenues to total EUR4 billion, down from prior guidance of EUR5 billion.
...

[faultcode]

24.4.
China’s Covid Drugmakers Shares Jump Amid Concern Over New Virus Wave
https://uk.news.yahoo.com/china-covid-drugmakers-surge-amid-…
...
Growing concerns that China may be facing a new Covid wave fueled a surge in shares of the nation’s drugmakers Monday as the public fretted over waning immunity.
...

Meanwhile, Zhang Wenhong, one of China’s top Covid advisers, said at a summit last week that vulnerable groups should get a booster shot and citizens should stock up on drugs in preparation for the arrival of new variants.
...

[faultcode]

wenn China den "BioNTech-Piks" in größerem Umfang als bislang bekommen sollte, dann geht's hier vermutlich wieder ab -- mit Angriff auf das Gap vom Januar mMn:

[faultcode]

7.11.
...
BioNTech raises the lower end of its 2022 full year financial guidance to include estimated COVID-19 vaccine revenue of €16 - 17 billion
...
BioNTech Announces Third Quarter 2022 Financial Results and Corporate Update
https://www.ariva.de/news/biontech-announces-third-quarter-2…


..und wieder retour:

[faultcode]

28.8.
WSJ: New omicron-specific COVID booster expected to be approved before trial data is in
https://www.marketwatch.com/story/new-omicron-specific-covid…
...
‘The vaccines are safe,’ FDA commissioner says; clearance is similar to approach FDA takes with flu shots

The Food and Drug Administration is expected to authorize new COVID-19 booster shots this week without a staple of its normal decision-making process: data from a study showing whether the shots were safe and worked in humans.

The shots, modified to target the latest versions of the omicron variant, won’t have finished testing in humans when the FDA makes its decisions.

Instead, the agency plans to assess the shots using data from other sources such as research in mice, the profiles of the original vaccines and the performance of earlier iterations of boosters targeting older forms of omicron.

“Real world evidence from the current mRNA COVID-19 vaccines, which have been administered to millions of individuals, show us that the vaccines are safe,” FDA Commissioner Robert Califf said in a recent tweet. The FDA pointed to Califf’s tweets when asked for comment.
...

[faultcode]

Antwort auf Beitrag Nr.: 72.117.669 von faultcode am 03.08.22 16:15:00

[faultcode]

Antwort auf Beitrag Nr.: 71.894.871 von faultcode am 30.06.22 23:32:48

das sieht ganz konstruktiv aus derzeit:

[faultcode]

Antwort auf Beitrag Nr.: 71.635.974 von faultcode am 23.05.22 15:41:37

mind the gap (2)

[Hoing-Going]

!

Dieser Beitrag wurde von SelfMODus moderiert. Grund: Fragen zur Moderation bitte direkt an den Moderator oder an den CommunitySupport.

[Guru-Neu]

!

Dieser Beitrag wurde von SelfMODus moderiert. Grund: Fragen zur Moderation bitte direkt an den Moderator oder an die CommunityLeitung